1921
Volume 100, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic blood condition, can result in kernicterus at birth, and later in life as severe hemolysis on exposure to certain infections, foods, and drugs. The unavailability of point-of-care tests for G6PD deficiency is a barrier to routine curative treatment of malaria with 8-aminoquinolines, such as primaquine. Two quantitative reference tests (Trinity Biotech, Bray, Ireland and Pointe Scientific, Canton, MI; Cat No. G7583) and the point-of-care STANDARD G6PD test (SD Biosensor, Suwon, South Korea) were evaluated. The STANDARD G6PD test was evaluated at multiple temperatures, in anticoagulated venous and capillary samples, including 79 G6PD-deficient and 66 intermediate samples and across two laboratories, one in the United States and one in Thailand. The STANDARD test performed equivalently to a reference assay for its ability to diagnose G6PD deficiency (< 30% normal) with a sensitivity of 100% (0.95 confidence interval [CI]: 95.7–100) and specificity of 97% (0.95 CI: 94.5–98.5), and could reliably identify females with less than 70% normal G6PD activity with a sensitivity of 95.5% (0.95 CI: 89.7–98.5) and specificity of 97% (0.95 CI: 94.5–98.6). The STANDARD G6PD product represents an opportunity to diagnose G6PD deficiency equally for males and females in basic clinical laboratories in high- and low-resource settings. This quantitative point-of-care diagnostic test for G6PD deficiency can provide equal access to safe radical cure of cases in high- and low-resource settings, for males and females and may support malaria elimination, in countries where is endemic.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0612
2018-10-22
2019-11-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/100/1/tpmd180612.html?itemId=/content/journals/10.4269/ajtmh.18-0612&mimeType=html&fmt=ahah

References

  1. Luzzatto L, Nannelli C, Notaro R, , 2016. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am 30: 373393. [Google Scholar]
  2. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E, , 2012. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations. Blood Cells Mol Dis 48: 154165. [Google Scholar]
  3. Cunningham AD, Hwang S, Mochly-Rosen D, , 2016. Glucose-6-phosphate dehydrogenase deficiency and the need for a novel treatment to prevent kernicterus. Clin Perinatol 43: 341354. [Google Scholar]
  4. Olusanya BO, Emokpae AA, Zamora TG, Slusher TM, , 2014. Addressing the burden of neonatal hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency. Acta Paediatr 103: 11021109. [Google Scholar]
  5. Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, Anstey NM, Price RN, , 2013. Major burden of severe anemia from non-falciparum malaria species in southern Papua: a hospital-based surveillance study. PLoS Med 10: e1001575; discussion e1001575. [Google Scholar]
  6. Kenangalem E, Karyana M, Burdarm L, Yeung S, Simpson JA, Tjitra E, Anstey NM, Poespoprodjo JR, Price RN, Douglas NM, , 2016. Plasmodium vivax infection: a major determinant of severe anaemia in infancy. Malar J 15: 321. [Google Scholar]
  7. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, Nosten F, , 1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg 93: 433438. [Google Scholar]
  8. Robinson LJ, 2015. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med 12: e1001891. [Google Scholar]
  9. Llanos-Cuentas A, 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383: 10491058. [Google Scholar]
  10. Baird JK, , 2015. Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency. BMC Med 13: 296. [Google Scholar]
  11. Ainoon O, Alawiyah A, Yu YH, Cheong SK, Hamidah NH, Boo NY, Zaleha M, , 2003. Semiquantitative screening test for G6PD deficiency detects severe deficiency but misses a substantial proportion of partially-deficient females. Southeast Asian J Trop Med Public Health 34: 405414. [Google Scholar]
  12. Espino FE, Bibit JA, Sornillo JB, Tan A, von Seidlein L, Ley B, , 2016. Comparison of three screening test kits for G6PD enzyme deficiency: implications for its use in the radical cure of vivax malaria in remote and resource-poor areas in the Philippines. PLoS One 11: e0148172. [Google Scholar]
  13. LaRue N, 2014. Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg 91: 854861. [Google Scholar]
  14. Nantakomol D, Paul R, Palasuwan A, Day NP, White NJ, Imwong M, , 2013. Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency. Malar J 12: 289. [Google Scholar]
  15. Domingo GJ, Advani N, Satyagraha AW, Sibley CH, Rowley E, Kalnoky M, Cohen J, Parker M, Kelley M, , 2018. Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. Int Health, doi:10.1093/inthealth/ihy060. [Google Scholar]
  16. Chu CS, 2017. Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens. PLoS Med 14: e1002224. [Google Scholar]
  17. Bancone G, Gornsawun G, Chu CS, Porn P, Pal S, Bansil P, Domingo GJ, Nosten F, , 2018. Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. PLoS One 13: e0196716. [Google Scholar]
  18. Bhutani VK, Kaplan M, Glader B, Cotten M, Kleinert J, Pamula V, , 2015. Point-of-care quantitative measure of glucose-6-phosphate dehydrogenase enzyme deficiency. Pediatrics 136: e1268e1275. [Google Scholar]
  19. Brito MA, Peixoto HM, Almeida AC, Oliveira MR, Romero GA, Moura-Neto JP, Singh N, Monteiro WM, Lacerda MV, , 2016. Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon. Rev Soc Bras Med Trop 49: 446455. [Google Scholar]
  20. Domingo GJ, 2013. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J 12: 391. [Google Scholar]
  21. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, Bansil P, McGray S, Domingo GJ, Nosten FH, , 2015. Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. Am J Trop Med Hyg 92: 818824. [Google Scholar]
  22. Kumar R, Indrayan A, , 2011. Receiver operating characteristic (ROC) curve for medical researchers. Indian Pediatr 48: 277287. [Google Scholar]
  23. Belfield KD, Tichy EM, , 2018. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Health Syst Pharm 75: 97104. [Google Scholar]
  24. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI, , 2013. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 81: 133201. [Google Scholar]
  25. Osorio L, 2015. Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects. Am J Trop Med Hyg 92: 2227. [Google Scholar]
  26. Rueangweerayut R, 2017. Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers. Am J Trop Med Hyg 97: 702711. [Google Scholar]
  27. World Health Organization, 2016. Technical Specifications Series for Submission to WHO Prequalification—Diagnostic Assessment: In Vitro Diagnostics Medical Devices to Identify Glucose-6-Phosphate Dehydrogenase (G6PD) Activity. Available at: http://apps.who.int/iris/bitstream/handle/10665/252628/9789241511865-eng.pdf?sequence=1. Accessed October 2, 2018.
  28. Chiang SH, Fan ML, Hsiao KJ, , 2008. External quality assurance programme for newborn screening of glucose-6-phosphate dehydrogenase deficiency. Ann Acad Med Singapore 37: 8487. [Google Scholar]
  29. Roper DR, De la Salle B, Soni V, Fletcher K, Green JA, , 2017. Abrogation of red blood cell G6PD enzyme activity through heat treatment: development of survey material for the UK NEQAS G6PD scheme. Int J Lab Hematol 39: 308316. [Google Scholar]
  30. Tang J, Zhou X, Liu X, Ning L, Zhou W, He Y, , 2017. External quality assessment program for detection of glucose-6-phosphate dehydrogenase deficiency in the Guangxi region. Exp Ther Med 14: 20212024. [Google Scholar]
  31. Tan IK, Whitehead TP, , 1969. Automated fluorometric determination of glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) activities in red blood cells. Clin Chem 15: 467478. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0612
Loading
/content/journals/10.4269/ajtmh.18-0612
Loading

Data & Media loading...

Supplemental files

  • Received : 25 Jul 2018
  • Accepted : 17 Sep 2018
  • Published online : 22 Oct 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error